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Abstract
Mutations in the gene for muscle phosphofructo-1-kinase (PFKM), a key regulatory enzyme of glycolysis, cause Type VII
glycogen storage disease (GSDVII). Clinical manifestations of the disease span from the severe infantile form, leading to
death during childhood, to the classical form, which presents mainly with exercise intolerance. PFKM deficiency is
considered as a skeletal muscle glycogenosis, but the relative contribution of altered glucose metabolism in other tissues to
the pathogenesis of the disease is not fully understood. To elucidate this issue, we have generated mice deficient for PFKM
(Pfkm
2/2). Here, we show that Pfkm
2/2 mice had high lethality around weaning and reduced lifespan, because of the
metabolic alterations. In skeletal muscle, including respiratory muscles, the lack of PFK activity blocked glycolysis and
resulted in considerable glycogen storage and low ATP content. Although erythrocytes of Pfkm
2/2 mice preserved 50% of
PFK activity, they showed strong reduction of 2,3-biphosphoglycerate concentrations and hemolysis, which was associated
with compensatory reticulocytosis and splenomegaly. As a consequence of these haematological alterations, and of
reduced PFK activity in the heart, Pfkm
2/2 mice developed cardiac hypertrophy with age. Taken together, these alterations
resulted in muscle hypoxia and hypervascularization, impaired oxidative metabolism, fiber necrosis, and exercise
intolerance. These results indicate that, in GSDVII, marked alterations in muscle bioenergetics and erythrocyte metabolism
interact to produce a complex systemic disorder. Therefore, GSDVII is not simply a muscle glycogenosis, and Pfkm
2/2 mice
constitute a unique model of GSDVII which may be useful for the design and assessment of new therapies.
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Introduction
Phosphofructo-1-kinase (PFK) is a tetrameric enzyme that
phosphorylates fructose-6-phosphate to fructose-1,6-bisphosphate,
committing glucose to glycolysis. Three PFK isoenzymes, encoded
by separate genes, have been identified in mammals: muscle-type
(PFKM), liver-type (PFKL), and platelet-type (PFKP), all of which
are expressed in a tissue specific manner [1]. Thus, skeletal muscle
expresses only PFKM homotetramers, liver mainly PFKL
homotetramers, although it can also express M- and P-type
subunits, while erythrocytes contain PFKM and PFKL hetero-
tetramers [2,3]. Several mutations in PFKM cause type VII
glycogen storage disease (GSDVII), which is a rare disease
described by Tarui (Tarui’s disease) [4]. GSDVII is inherited as
an autosomal recessive trait and patients show loss of PFK activity
in skeletal muscle and also partial deficiency in erythrocytes.
Although GSDVII is characterized by accumulation of glycogen in
skeletal muscle and hemolysis, there are several subtypes with
different clinical features. No genotype-phenotype correlation
explaining the phenotypic heterogeneity of the disease has been
described [5]. It can be detected as a severe form with onset in
infancy with hypotonia, limb weakness, progressive myopathy and
respiratory failure leading to death early in the childhood [6,7].
Neonatal mortality may be responsible for the low number of cases
diagnosed. Adult patients with the classical form of the disease
develop myopathy with muscle cramps and myoglobinuria when
exercised as well as compensated haemolytic anemia.
GSDVII is considered as a muscle glycogenosis. Although,
alterations in oxidative metabolism and bioenergetics in skeletal
muscle have also been described in human patients, few data on
metabolicandfiberstructural changesareavailable.Inaddition,the
contribution of altered glucose metabolism in other tissues to the
pathogenesis of the disease is not fully understood and may also lead
to misdiagnosis [8]. No therapies are available for GSDVII patients
and development of effective treatments requires both understand-
ing the molecular mechanisms that lead to the disease and the
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Inherited PFKM deficiency has only been described in dogs [9,10].
However, PFKM deficient dogs exhibit mild muscle disease not
closely reproducing the human muscle pathology [11]. In the
present study, to determine the molecular mechanisms underlying
this disease, we have generated mice lacking the muscle isoform of
PFK. We found that PFKM deficiency leads to marked alterations
in muscle bioenergetics and erythrocyte metabolism that interact to
produce the complex pathology characteristic of GSDVII. The
availability of the Pfkm
2/2 mouse model allows the study of
GSDVII as a systemic disorder, not simply as muscle glycogenosis.
Results
Pfkm
2/2 mice exhibit high lethality and skeletal muscle
glycogenosis
To generate Pfkm deficient mice, standard gene-targeting
methods in mouse embryonic stem cells were used. Homologous
recombination of the targeting construct resulted in the deletion of
the 59 promoter region and exon 3, which contains the translation
start codon (Figure 1A). The presence of heterozygous and
homozygous (Pfkm
+/2 and Pfkm
2/2) mice was confirmed by
Southern blot (data not shown) and by PCR (Figure 1B). Pfkm
+/2
mice were viable and fertile while Pfkm-null mice presented high
lethality around weaning (about 60%) and those surviving died
early during adulthood, at around 3 to 6 month of age, although
few animals survived for more than one year.
Pfkm
+/2 mice showed 50% lower muscle Pfkm expression and
activity (Figure 1C and 1D). However, this lower enzyme activity
in Pfkm
+/2 mice did not alter any metabolic parameter, such as
glucose-6-phosphate and glycogen levels (data not shown),
indicating that half of normal PFK activity is sufficient to prevent
metabolic alterations, as observed in heterozygous humans [12].
No Pfkm mRNA transcript was observed in skeletal muscle of
Pfkm
2/2 mice (Figure 1C), in agreement with the lack of enzyme
activity (Figure 1D). This deficiency led to increased glucose-6-
phosphate (Figure 1E), intracellular glucose (Figure 1F) and
glycogen (Figure 1G) content in skeletal muscle. Considerable
glycogen storage was also evidenced by histochemical analysis of
Pfkm
2/2 skeletal muscle (Figure 2A). Furthermore, electron
microscopy revealed very high subsarcolemmal and intermyofi-
brillar accumulation of glycogen, which altered fiber morphology
(Figure 2B). In addition, Pfkm
2/2 mice showed lower serum
lactate levels (Figure 1H), suggesting lower flux through glycolysis
in skeletal muscle. Nevertheless, these mice were normoglycemic
(Pfkm
+/+, 115612 vs. Pfkm
2/2, 113616 mg/dl; (n=12)). Consis-
tent with this, PFK activity and glucose metabolism were
unchanged in the liver (data not shown).
PFKM–deficient mice show exercise intolerance
Similar to patients with the classical form of GSDVII, two-
month-old Pfkm-null mice were intolerant to exercise. These mice
were unable to run for more than 1.5 min. in a treadmill before
developing severe muscle cramps, mainly in the rear limbs
(Figure 2C). When exercised, Pfkm
2/2 mice accumulated higher
levels of glucose-6-phosphate (Figure 1E), consistent with increased
muscle glucose uptake (Figure 1F) and mobilization of muscle
glycogen (Figure 1G).
Since the muscles of these mice fail to perform glycolysis, lactate
did not rise after exercise (Figure 1H). Furthermore, in Pfkm
2/2
skeletal muscles, ATP and ADP levels were lower even in the
resting state and fell with exercise (Figure 2D). These lower levels
of ATP agreed with the presence of muscle cramps after exercise,
spontaneous cramps during manipulation, and immediate rigor
mortis after death (not shown). Thus, skeletal muscle of Pfkm
2/2
mice was unable to meet the energy demand required to maintain
normal contractile activity.
Despite low ATP levels in Pfkm
2/2 mice, the expression of key
genes in oxidative metabolism and mitochondrial biogenesis was
higher than in wild-type mice, such as peroxisome proliferator-
activated receptor c coactivator-1a (PGC-1a), peroxisome pro-
liferator-activated receptor d (PPARd) muscle carnitine palmitoyl-
transferase 1 (M-CPT-1), citrate synthase (CS) and uncoupling
protein 2 (UCP2) (Figure 3A). Moreover, succinate dehydrogenase
and NADH-tetrazolium reductase activities, markers of oxidative
capacity, were also higher (Figure 3B). Up-regulation of the
expression of type I and IIa myosin heavy chain (MyHC-I and IIa)
oxidative-type fiber proteins, without changes in the glycolytic
MyHC-IIb, was also observed (Figure 3C). Consistent with these
findings, Pfkm
2/2 mice showed proliferation of enlarged mito-
chondria surrounded by glycogen depots (Figure 2B). Increased
expression of genes involved in glucose uptake and phosphoryla-
tion, glucose transporter 4 (GLUT4) and hexokinase-II (HK), was
found in skeletal muscle of Pfkm
2/2 mice (Figure 3D), which also
agreed with increased muscle glucose and glucose-6-phosphate
content (Figure 1E and 1F). In addition, the expression of the
pentose phosphate pathway transaldolase (TALDO1) and trans-
ketolase (TK) genes was higher in skeletal muscle of Pfkm
2/2 than
in wild-type mice (Figure 3E). Therefore, despite an increased
compensatory response, oxidative metabolism was unable to
overcome the glycolysis blockade in Pfkm
2/2 mice.
Lack of PFKM alters respiratory muscles and heart
RespiratoryskeletalmuscleswerealsoseverelyalteredinPfkm
2/2
mice. The lack of PFK activity in diaphragm, led to increased
glucose-6-phosphate and glycogen content (Figure 4A–4C). High
accumulation of glycogen was also observed in diaphragm
(Figure 4D) and intercostal muscle (Figure 4E) sections by PAS
Author Summary
Type VII glycogen storage disease (GSDVII), or Tarui
disease, is a rare genetic disorder characterized by
glycogen accumulation in skeletal muscle. The molecular
cause is loss of activity of the muscle isoform of
phosphofructokinase (PFK), which phosphorylates fruc-
tose-6-phosphate to fructose-1,6-bisphosphate, commit-
ing glucose to glycolysis. Entry of fructose-6-phosphate
into glycolysis is thus blocked, increasing glycogen
synthesis and accumulation. Clinical manifestations of
the disease are heterogeneous, ranging from exercise
intolerance to early childhood death. To further under-
stand the human pathology, we generated mice lacking
muscle PFK. As in human patients, these mice showed
severe exercise intolerance, hemolysis, and most died
young. Lack of glycolysis in skeletal muscle also causes
alterations in bioenergetics and compensatory changes in
key metabolic genes. Additionally, although erythrocytes
retained 50% of normal PFK activity, their overall
functionality was impaired, aggravating the muscle
dysfunction. Moreover, marked metabolic alterations in
the heart lead to chronic hypertrophy, suggesting that
cardiac pathology in GSDVII may be underestimated or
misdiagnosed. This study indicates that this disease is
more complex than a muscle glycogenosis and that
symptoms other than those classically described should
be taken into consideration. Finally, this animal model will
enable us to develop new therapeutic approaches and
better diagnostic tools.
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the respiratory capacity of Pfkm
2/2 mice.
Cardiac muscle, which expresses the PFKM, PFKL and PFKP
[3], showed lower PFK activity in Pfkm
2/2 mice (about 20% of
wild-type) and higher glucose-6-phosphate and glycogen levels
(Figure 5A–5C). In addition, increased glycogen storage was also
evident in electron microscopy sections of cardiac muscle
(Figure 5D). Two-month-old Pfkm
2/2 mice showed increased
(about 55%) heart weight (Pfkm
+/+, 4.460.1 mg/g b.w. vs. Pfkm
2/2,
6.960.3 mg/g b.w.; (n=5) p,0.01) and developed cardiac
hypertrophy and evident cardiomegaly with age (Figure 5E and
5F). Moreover, left ventricle enlargement without interstitial fibrosis
was observed after Masson trichromic staining of longitudinal
sections of Pfkm
2/2 hearts (Figure 5G).
Pfkm
2/2 mice develop hemolysis, reticulocytosis and
splenomegaly. Erythrocytes express both PFKM and PFKL
isoenzymes [13]. Consistent with the lack of PFKM in Pfkm
2/2
mice, erythrocytes showed 50% lower PFK activity and
accompanying glucose-6-phosphate accumulation (Figure 6A
and 6B). This correlated with lower 2,3-bisphosphoglycerate
(2,3-BPG) levels (Figure 6C). These metabolic alterations
resulted in increased osmotic fragility of erythrocytes (data not
shown) and severe hemolysis. Thus, Pfkm
2/2 mice had very high
levels of serum bilirubin (Figure 6D) and lactate dehydrogenase
and lower hematocrit (data not shown). As a consequence, Pfkm
2/2
mice showed compensatory reticulocytosis (Figure 6E and 6F) and
splenomegaly (Figure 6G and 6H), which correlated to increased
hematopoietic precursors from spleen, but not bone marrow
(Figure 6I and 6J). These alterations are features of GSDVII, in
which patients show compensated hemolytic anemia with increased
serum bilirubin and reticulocyte count [14].
Skeletal muscle of Pfkm
2/2 mice presents increased
vascularization and fiber necrosis and regeneration
The decrease of erythrocyte 2,3-BPG levels increases hemoglo-
bin affinity for oxygen and thus impairs oxygen extraction from
hemoglobin [15]. Thus, the inability of oxidative metabolism to
compensate for glycolysis blockade in Pfkm
2/2 skeletal muscle may
also be due to decreased availability of oxygen to generate
sufficient energy. Furthermore, consistent with decreased oxygen
availability and marked hemolysis, skeletal muscle of Pfkm
2/2
mice showed hypoxia, evidenced by higher expression (6-fold) of
the hypoxia induced factor 1a (HIF-1 a) (Figure 7A). Moreover,
Figure 1. Generation of Pfkm
2/2 mice and the effect of Pfkm ablation on skeletal muscle glucose metabolism. (A) Schematic
representationof the wild-type Pfkm locus (top), targeting vector (middle) andtargeted allele (bottom). Thepositions of HindIII (H)andXbaI (X) cleavage
sites, the neo
R (neo) and herpes simplex virus thymidine kinase (HSV-tk) genes, and the location of PCR primers used to detect wild-type (PFK-Fw and
PFK-Rev) and targeted (Neo and PFK-Rev) alleles are shown. (B) PCR analysis of DNA from wild type (+/+), Pfkm
+/2 (+/2) and Pfkm
2/2 (2/2) mice using
the primers shown in (A). The0.6 Kb band correspondsto thewild-type allele andthe0.7 Kb band to the mutantallele. (C)Expressionof Pfkm in skeletal
muscle. Total RNA was obtained from gastrocnemius muscle and analyzed by Northern blot. A representative Northern blot hybridized with a Pfkm
probe is shown. (D) PFK activity was determined in skeletal muscle as indicated in Materials and Methods. Basal PFK activity in wild-type mice was
3662.4 U/g tissue. (E–G) Glucose-6-phosphate(E), glucose(F)andglycogen(G)concentrationswere determinedinperchloricextractsofskeletal muscle
from 2–3 month-old wild-type (+/+) and and Pfkm
2/2 (2/2) mice, in rest and after exercise (5 min), as indicated in Materials and Methods. (H) Serum
lactate levels in wild-type (+/+) andPfkm
2/2 (2/2) mice,in rest andafter exercise (5 min). Results in D-Haremean6SEMof five to eight mice pergroup.
*P,0.05, **P,0.01 vs. wild-type.
doi:10.1371/journal.pgen.1000615.g001
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M (PK-M), lactate dehydrogenase (LDH), and glucose transporter-
1 (GLUT1), were up-regulated in this tissue (Figure 7A). This
increase in GLUT1 was also consistent with the observed higher
intracellular glucose (Figure 1F). The increase in HIF-1a was also
parallel to increased vascular endothelial growth factor (VEGF)
expression (Figure 7B). In addition, it has been described in
skeletal muscle that PGC1a is induced by a lack of oxygen and
that PGC1a powerfully regulates VEGF expression [16], which
may have also occurred in Pfkm
2/2 mice. The increase in VEGF
led to hypervascularization, as evidenced by greater immuno-
staining of the platelet endothelial cell adhesion molecule
(PECAM-1), an endothelial cell marker, and collagen IV, a
basement membrane marker (Figure 7B). Furthermore, the
chronic lower levels of ATP in skeletal muscle of Pfkm
2/2 mice
resulted in multiple sites of muscle fiber degeneration and necrosis,
characterized by inflammatory infiltration of mononucleated cells
and by phagocytosis of necrotic fibers (Figure 7C). In addition,
intense skeletal muscle regenerative activity was evidenced by wide
distribution of centrally-located nuclei fibers in Pfkm
2/2 mice
(Figure 7D). Thus, severe muscle fiber alterations, in addition to
glycogen accumulation, result from PFKM deficiency.
Discussion
In this study we show that mice with targeted ablation of the
muscle isoform of PFK develop myopathic and hemolytic features
similar to those noted in type VII glycogenosis in humans. The
early lethality observed in Pfkm
2/2 mice also resembled the most
severe variant of the disease, which presents in infancy and rapidly
proceeds to a progressive myopathy and death [6]. Importantly,
the full range of phenotypic changes we have observed in our
Figure 2. Pfkm
2/2 mice develop skeletal muscle glycogenosis and exercise intolerance. (A) Glycogen storage evidenced by PAS staining in
skeletal muscle sections from wild-type (WT) and Pfkm
2/2 mice. Scale bar 50 mm. (B) Transmission electron microscopic analysis of skeletal muscle.
Arrows show glycogen storage and asterisks point to mitochondria. Scale bar 1 mm. (C) Pfkm
2/2 mice showing severe muscle cramps after exercise
(5 min). (D) ATP and ADP content was determined in perchloric extracts of skeletal muscle from wild-type (+/+) and and Pfkm
2/2 (2/2) mice, in rest
and after exercise (5 min), as described in Materials and Methods. Results are mean6SEM of five mice per group. *P,0.05 vs. wild-type.
doi:10.1371/journal.pgen.1000615.g002
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since phenotypic heterogeneity is common. In addition, future
treatment strategies will need to consider the full extent of
pathogenesis to optimize effectivity and safety.
The increased glycogen and glucose-6-phosphate in skeletal
muscle observed in Pfkm
2/2 mice is the classic hallmark described
in biopsies of human patients with GSDVII. Suppression of
glycolysis impaired the use of glycogen as a fuel leading to
increased storage. Moreover, blood glucose cannot be metabolized
by the glycolytic pathway causing glucose-6-phosphate accumu-
lation in skeletal muscle. Allosteric activation of glycogen synthase
by glucose-6-phosphate may have contributed to increase glycogen
storage [17]. Skeletal muscle uses glucose, either blood- or
glycogen- derived, as the major fuel during muscular activity.
The impairment of the principal catabolic pathway in skeletal
muscle of Pfkm
2/2 mice led to energetic deprivation, which
resulted in failure to perform exercise. Similarly, PFKM deficient
patients show severe alterations in muscle bioenergetics leading to
muscle weakness and exercise intolerance [18,19]. Ineffective
utilization of glycogen in patients with type V glycogen storage
(GSDV) or McArdle’s disease also leads to impairment of exercise
capability. GSDV results from deficiency of the muscle isoform of
glycogen phosphorylase, which leads to blockade of glycogen
breakdown and to high glycogen storage in skeletal muscle [20].
However, GSDV patients show exercise tolerance after carbohy-
drate infusion since they can metabolize circulating glucose
because glycolytic flux is preserved [21]. In contrast, in GSDVII
patients, glucose infusion induces exertional fatigue attributed to
an insulin-mediated decreased availability of blood free fatty acids
and ketone bodies [22].
Muscle fibers of Pfkm
2/2 mice failed to generate enough ATP to
maintain contractile activity, and mice developed muscle cramps
early during the exercise test and with manipulation. In addition,
even in rested state, Pfkm
2/2 mice showed low levels of ATP in the
Figure 3. Effects of PFKM deficiency in skeletal muscle markers. (A) Expression of key genes in oxidative metabolism in skeletal muscle of
wild-type and Pfkm
2/2 mice: Peroxisome proliferator-activated receptor c coactivator-1a (PGC-1a), peroxisome proliferator-activated receptor d
(PPARd), carnitine palmytoiltransferase-1 (M-CPT-1), citrate sinthase (CS) and uncoupling protein 2 (UCP-2). (B) Histochemical staining for succinate
dehydrogenase (SDH) and NADH-tetrazolium reductase (NADH-TR) activities in skeletal muscle of wild-type and Pfkm
2/2 mice. Scale bar 25 mm. (C)
Expression of myosin heavy chains in skeletal muscle of wild-type and Pfkm
2/2 mice: Type I, IIa ,and IIb myosin heavy chains (MyHC-I, MyHC-IIa,
MyHC-IIb). (D) Expression of the key genes in skeletal muscle glucose uptake, glucose transporter 4 (GLUT4) and hexokinase-II (HKII), in wild-type and
Pfkm
2/2 mice. (E) Expression of pentose phosphate pathway genes, transaldolase (TALDO1) and transketolase (TK), in skeletal muscle of wild-type
and Pfkm
2/2 mice. Relative expression in A, C, D and E was determined by quantitative PCR analysis of total RNA from skeletal muscle, as indicated in
Materials and Methods. Results are mean6SEM of five mice per group. *P,0.05 vs. wild-type.
doi:10.1371/journal.pgen.1000615.g003
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mitochondrial myopathy in other animal models [23,24]. Physio-
logical situations involving energy deprivation in skeletal muscle, like
exercise and fasting, lead to adaptive changes towards the oxidation
of fat as a fuel [25]. In skeletal muscle of Pfkm
2/2 mice, increased
expression of oxidative marker genes and proliferation of enlarged
mitochondria revealed an attempt to overcome glycolysis deficiency
by shifting substrate metabolism toward a higher reliance on
oxidative metabolism. Factors involved in this adaptation included
PGC-1a,P P A R d and muscle CPT-1, which are responsible for
mitochondrial biogenesis, oxidative phosphorylation and fatty acid
oxidation [25]. Furthermore, PGC-1a and PPARd may have been
involved in structural changes towards the formation of oxidative
muscle fibers by increasing the expression of MyHC-I [26,27].
Moreover, PGC-1a up-regulation was probably responsible for the
increased expression of GLUT-4 and HK-II in skeletal muscle of
Pfkm
2/2 mice [28]. This led to enhanced glucose uptake and
phosphorylation, also consistent with the high levels of glucose and
glucose-6-phosphate detected in skeletal muscle of Pfkm
2/2 mice. In
addition, the increased expression of transaldolase and transketolase
enzymes suggested that glucose could be used through the pentose
phosphate pathway in skeletal muscle of Pfkm
2/2 mice. However,
despite these compensatory responses, oxidative metabolism was
unable to overcome the glycolysis blockade in Pfkm
2/2 mice.
Anaplerosis of the tricarboxylic acid (TCA) or Krebs cycle
plays a key role in oxidative metabolism in skeletal muscle by
providing the TCA cycle with intermediates to permit its
continued function. Impaired production of glycolytic substrates
could limit oxidative metabolism by reducing concentrations of
Krebs cycle intermediates [29,30]. Blockade of glucose utiliza-
Figure 4. Effect of Pfkm ablation in diaphragm glucose metabolism and in respiratory muscle glycogen storage. (A) PFK activity was
determined in diaphragm extracts as indicated in Materials and Methods. Basal PFK activity in wild-type mice was 26.564.2 U/g tissue. (B,C) Glucose-
6-phosphate (B) and glycogen concentrations (C) were determined in diaphragm perchloric extracts from wild-type (+/+) and Pfkm
2/2 (2/2) mice, as
indicated in Materials and Methods. Results are mean6SEM of five mice per group. *P,0.05, **P,0.01 vs. wild-type. (D,E) Glycogen storage
evidenced by PAS staining in diaphragm sections (D) from wild-type (wt) and Pfkm
2/2 mice (scale bar 50 mm) and in intercostal muscle sections (E)
from Pfkm
2/2 mice (scale bar 300 mm). IC, intercostal muscles; R, rib.
doi:10.1371/journal.pgen.1000615.g004
PFKM Deficiency Causes a Systemic Disorder
PLoS Genetics | www.plosgenetics.org 6 August 2009 | Volume 5 | Issue 8 | e1000615tion through the glycolysis pathway in skeletal muscle of Pfkm
2/2
mice may lead to impaired production of the glucose-derived
anaplerotic substrates phosphoenolpyruvate and pyruvate. Dys-
regulation of the TCA cycle intermediates probably impaired
oxidative phosphorylation and the ability of skeletal muscle in
Pfkm
2/2 mice to generate an adequate amount of ATP. The
significance of the regulation of TCA cycle intermediates in the
control of skeletal muscle energy metabolism has clearly been
shown in mice overexpressing phosphoenolpyruvate carboxyki-
nase (PEPCK-C). PEPCK-C transgenic mice show increased
oxidative capacity in skeletal muscle leading to enhanced exercise
performance [31].
Figure 5. Pfkm
2/2 mice show altered heart glucose metabolism and develop cardiomegaly with age. (A) PFK activity was determined in
heart extracts. Basal PFK activity in wild-type mice was 27.465.4 U/g tissue. (B,C) Glucose-6-phosphate (B) and glycogen concentrations (C) were
determined in heart perchloric extracts from 2-month-old wild-type (+/+) and Pfkm
2/2 (2/2) mice. Results are mean6SEM of five mice per group.
*P,0.05, **P,0.01 vs. wild-type. (D) Transmission electron microscopic analysis of cardiac muscle. Arrows show glycogen storage. Scale bar 2 mm.
(E,F) One-year-old Pfkm
2/2 mice develop cardiac hypertrophy, evidenced by hematoxilin-eosin staining of heart sections (scale bar 1 mm) (E) and
cardiomegaly (F). (G) Longitudinal sections of heart from 3-month-old mice stained with Masson trichromic reagent (scale bar 1 mm). Inset shows
septum sections (scale bar 50 mm).
doi:10.1371/journal.pgen.1000615.g005
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anemia due to reduction in the erythrocyte PFK activity. Pfkm
2/2
mice clearly underwent hemolysis and compensatory erythropoi-
esis evidenced by marked reticulocytosis. Since erythrocytes lack
mitochondria, glycolysis is essential for their energy metabolism.
Consequently, although erythrocytes of Pfkm
2/2 mice preserve
about half of the PFK activity observed in wild-type mice, it was
not enough to maintain erythrocyte integrity. Moreover, the
kinetic properties of residual L homotetramer may turn it
somehow dysfunctional in Pfkm
2/2 erythrocytes [32]. Removal
of defective erythrocytes was probably responsible for the
increased spleen size in Pfkm
2/2 mice. Splenomegaly has broadly
been described as a result of hemolysis or hematopoietic stress in
several diseases [33,34]. Thus, increased hematopoiesis may have
also contributed to increase spleen size in Pfkm
2/2 mice. Similar
hematological features are found in spontaneous mutant mice with
reduced activity of the glycolytic enzyme pyruvate kinase (Pk-1
slc)
in red blood cells [35].
Lower PFK activity in erythrocytes of Pfkm
2/2 mice led to
lower concentrations of glycolytic intermediates and 2,3-BPG. In
turn, low levels of 2,3-BPG increase the oxygen affinity of
hemoglobin, reducing oxygen delivery to the tissues and
stimulating erythropoiesis. Skeletal muscle requires large amounts
of oxygen during intense exercise and alterations in the affinity of
hemoglobin for oxygen could impair muscle performance [15].
Consistent with decreased oxygen availability and marked
hemolysis, skeletal muscle of Pfkm
2/2 mice showed features of
hypoxia and angiogenesis together with necrosis and intense
regenerative activity. This decreased oxygen availability probably
contributed to impair the compensatory oxidative metabolism in
Figure 6. Reduction of erythrocyte PFK activity leads to hemolysis, reticulocytosis, and splenomegaly. (A) PFK activity was determined in
blood cell lysates from wild-type (+/+)a n dPfkm
2/2 (2/2) mice as indicated in Materials and Methods. (B,C) Glucose-6-phosphate (B) and 2,3-
bisphosphoglycerate(2,3-BPG)(C) concentrations weredeterminedinbloodcellperchloricextractsasindicatedinMaterials andMethods. (D–F) Pfkm
2/2
show high serum bilirubin levels (D) and reticulocyte number (E,F). New methylene blue stained blood samples were extended on slices (E) and counted
(F). Arrows indicate reticulocytes. Scale bar 15 mm. (G,H) Splenomegaly in Pfkm
2/2 mice. A high increase in spleen size (G) and weight (H) was observed.
Scale bar 5 mm. (I,J) Hematopoietic precursors in cultured cells from spleen (I) and femur (J) from wild-type (+/+)a n dPfkm
2/2 (2/2) mice. Results are
mean6SEM of five to eight mice per group. **P,0.01 vs. wild-type.
doi:10.1371/journal.pgen.1000615.g006
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functionality. In addition, changes in oxygen delivery to tissues
may result in lower respiratory and cardiac function in Pfkm
2/2
mice.
Involvement of respiratory and cardiac muscles in the
pathogenesis of GSDVII is not clearly understood. Myopathic
alterations in the respiratory muscles are responsible for loss of
respiratory function and even death in a wide spectrum of muscle
disorders [36,37] and other glycogen storage diseases [38,39]. In
addition, premature death due to a respiratory failure is a feature
of the severe infantile form of GSDVII [6,40]. The structural and
metabolic abnormalities observed in the diaphragm and respira-
tory muscles of Pfkm
2/2 mice suggest impaired respiratory
function and may have contributed to the lethality observed in
these mice. On the other hand, cardiac abnormalities, such as low
voltage electrocardiogram, tachycardia, ventricular hypertrophy
and atrium enlargement, have only been described in a few
patients [41]. Cardiac hypertrophy may result as an adaptive
response to increased workload, and prolonged hypertrophy is
associated with increased risk for sudden death or progression to
heart failure [42]. Although most frequent causes of heart
hypertrophy are chronic hypertension, exercise, myocardial
infarction or aortic valve stenosis, several reports point to defects
in cardiac energetic metabolism underlying heart enlargement
[43]. Thus, heart specific ablation of GLUT-4 glucose transporter
or deletion of the adenine nucleotide translocator-1 gene lead to
heart hypertrophy in mice [24,44]. Therefore, altered glucose
metabolism in the heart of Pfkm
2/2 mice may have led to
deficient energy production in cardiomyocyte and compensatory
chronic heart hypertrophy, which probably increased mortality in
these mice. These results suggest that the cardiac pathology in
GSDVII may probably be underestimated or misdiagnosed [41].
In addition, this study indicates that symptoms other than
classically described may be taken into consideration for the
diagnostic of the GSDVII.
In summary, these results indicate that the skeletal and cardiac
muscle impairments observed in Pfkm
2/2 mice interact with
disturbed erythrocyte metabolism to produce the heterogeneous
and complex pathology characteristic of type VII glycogen storage
disease. The availability of this murine model of GSDVII allows
determination of the role of such metabolic alterations in different
tissues and organs together with their interactions, and, impor-
tantly, allows the study of GSDVII as a systemic disorder, not
simply as a muscle glycogenosis. Moreover, Pfkm
2/2 mice
Figure 7. Pfkm
2/2 mice show increased skeletal muscle hypoxic markers, vascularization, and fiber necrosis. (A) The expression of the
hypoxia-induced factor (HIF-1a), pyruvate kinase (PK-M), lactate dehydrogenase (LDH), and glucose transporter-1 (GLUT-1) in skeletal muscle of
Pfkm
2/2 mice was determined by quantitative PCR analysis, as indicated in Materials and Methods. Results are mean6SEM of four mice per group.
*P,0.05, **P,0.01 vs. wild-type. (B) Skeletal muscle sections showed increased immunostaining for VEGF, leading to hypervascularization, as
evidenced by greater immunostaining for endothelial cell marker PECAM-1 (scale bar 25 mm) and collagen IV (scale bar 10 mm). Arrows show blood
vessels around muscle fiber. (C) Fiber necrosis in skeletal muscle sections of Pfkm
2/2 mice. Arrows indicate cell infiltration of necrotic fibers (scale bar
25 mm). (D) Muscle fiber regeneration is evidenced by multiple centrally located nuclei (arrows) (scale bar 25 mm).
doi:10.1371/journal.pgen.1000615.g007
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very useful for the design and assessment of new therapeutic
interventions for this disease.
Materials and Methods
Generation of Pfkm
2/2 mice
Genomic clones for mouse Pfkm were isolated from a mouse
129/SvJ library (Stratagene). To construct the targeting vector,
two fragments of the genomic DNA flanking the exon 3 were
subcloned at convenient restriction sites in the pPNT vector.
Linearized pPTN/pfkm was transfected into 129/SvJ derived
embryonic stem cells (ES) (CMTI-1, Speciality Media). Selection
was performed with G418 and gancyclovir, and resistant clones
were screened for homologous recombination by Southern blot.
Targeted ES cells were injected into blastocysts from C57BL/6J
mice and transferred into uteri of pseudopregnant females.
Chimeric males were mated to C57BL/6J females and the
offspring was screened by PCR analysis using both locus-specific
and Neo cassette-specific primers: PFK-Fw: 59-AATGCACTCC-
GATCTGCTCC-39; Neo: 59-CGCCTTCTATCGCCTTCTTG
ACGAGTTCTT-39; PFK-Rev: 59-GCAAGCAATGCCTAAA-
TCTG-39. Homozygous mutant mice were obtained by mating
heterozygous littermates. Mice were fed ad libitum with a standard
diet (Panlab, Barcelona, Spain) and maintained under a light-dark
cycle of 12 h (lights on at 9:00 A.M.). Animals were killed and
samples were taken between 9:00 and 10:00 A.M. In the
experiments described, male mice, aged 2–3 months were used
with littermates as controls. All experimental procedures involving
mice were approved by the Ethics Committee in Animal and
Human Experimentation of the Universitat Auto `noma de
Barcelona.
RNA analysis
Total RNA was obtained from skeletal muscle samples and
analyzed by Northern blot. Northern blots were hybridized to
32P-
labeled pfkm cDNA probe labeled following the method of random
oligopriming, as described by the manufacturer (Amersham
Corp.). For real-time qPCR, 1 mg of RNA samples was used as
a template to synthesize cDNA in a volume of 20 ml (Omniscript
kit, Qiagen). Oligo-dT was used as a primer for the reaction in the
presence of Protector RNase inhibitor (Roche). RT-PCR was
performed in a SmartCycler II (Cepheid) using QuantiTect SYBR
Green PCR kit (Qiagen). The sequences of the respective sense
and antisense oligonucleotide primers were: Primers sequences:
PGC-1a: (F) ATACCGCAAAGAGCACGAGAAG and (R) CT-
CAAGAGCAGCGAAAGCGTCACAG; PPARd: (F) TCCA-
TCGTCAACAAAGACGGG and (R) ACTTGGGCTCAAT-
GATGTCAC; M-CPT1: (F) GCACACCAGGCAGTAGCTTT
and (R) CAGGAGTTGATTCCAGACAGGTA; CS: (F) TGCC-
CACACAAGCCATTTG and (R) CTGACACGTCTTTGC-
CAACTT; HIF-1a: (F) AGCCC TAGATGGCTTTGTGA and
(R) TATCGAGGCTGTGTCGACTG; PK-M: (F) CGATCT-
GTGGAGATGCTGAA and (R) AATGGGATCAGATGCAA-
AGC; LDH: (F) TGTCTCCAGCAAAGACTACTGT and (R)
GACTGTACTTGACAAT GTTGGGA; GLUT-1: (F) CAG-
TTCGGCTATAACACTGGTG and (R) GCCCCCGACAGA-
GAAGATG; MyHC-I: (F) AGAGGGTGGCAAAGTCACTG
and (R) GCCATGTCCTCGATCTTGTC; MyHC-IIa: (F) CGA-
TGA TCTTGCCAGTAATG and (R) TGATAACTGAGATA-
CCAGCG; MyHC-IIb: (F) ACAGACTAAAGTGAAAGCC and
(R) CTCTCAACAGAAAGATGGAT; GLUT4: (F) GACGGA-
CACTCCATCTGTTG and (R) CATAGCTCATGGCTGG
AACC; HKII: (F) GAAGGGGCTAGGAGCTACCA and (R)
CTCGGAG CACACGGAAGTT; TALDO1: (F) GATTCCAG-
GCCGTGTATCCAC and (R) AATCCCCTCCCAGGTTGAT-
GA; TKT: (F) TGGCATACACAGGCAAATACTT and (R)
TCCAGCTTGTAAATTCCAGCAA and 36B4: (F) GGCCCT-
GCACTCTCGCTTT and (R) TGCCAGGACGCGCTTGT.
Data was normalized with 36B4 gene values and analyzed as
previously described [45].
Enzyme and metabolite assays
To determine PFK activity and the concentration of metabolites
mice were anesthetized with a mixture of ketamine (100 mg/kg)
and xylacine (10 mg/kg). Afterwards, skeletal muscle was freeze
clamped in situ, and kept at 280uC until analysis. Diaphragm and
heart were rapidly excised, weighed, frozen in liquid nitrogen and
kept at 280uC. Heparinized blood samples were centrifuged, cells
collected and frozen. For PFK activity, samples were homogenized
in 10 volumes (1 ml/100 mg tissue) of an ice-cold buffer (pH 7.4)
containing 20 mM Tris-HCl, 100 mM KCl, 5 mM MgCl2,5m M
Phosphate Buffer and 30% Glycerol. Samples were centrifugued
and PFK activity was determined in the presence of 6 mM
fructose 6-phosphate and 18 mM glucose 6-phosphate by
spectrophotometric analysis as previously indicated [46]. The
concentrations of glycogen, glucose 6-phosphate, glucose and 2,3-
BPG were measured in perchloric extracts, which were adjusted to
pH 5 with 5 M K2CO3 to determine glycogen and glucose, and to
pH 7 for glucose 6-phosphate and 2,3-BPG. Glycogen levels were
measured using the a-amyloglucosidase method [47]. Glucose and
glucose 6-phosphate concentrations were determined enzymati-
cally [48]. 2,3-BPG was determined using a specific kit (Roche
Diagnostics GMBH). The concentration of ATP and ADP was
determined as described previously [49,50]. Serum lactate
dehydrogenase activity and total bilirubin and lactate levels were
measured in the autoanalyzer Pentra400 (ABX Diagnostics) using
specific kits (ABX Diagnostics). Glucose concentration in blood
was determined by using a Glucometer Elite (Bayer) following the
manufacturer’s instructions.
Exercise test
Mice were exercised for 5 min on an enclosed treadmill LE-
8708 (Panlab) supplied with an electrified grid at the rear of the
belt to provide motivation. The speed of the belt was 30 cm/sec.
Retyculocyte count and hematopoietic cultures
To determine the number of retyculocytes, blood samples were
stained with new methylene blue, extended on slices, and counted
under microscope. Hematopoietic cultures were performed in
extracts of bone marrow and spleen. Triplicate assays were done in
35 mm plates. Samples were cultured for 7 days at 37uC, 5% CO2
and 95% relative humidity in MethoCult GF M3434 medium
(StemCell Technologies Inc.). Colonies were counted under
inverted microscope including CFU-GM, BFU-E, and CFU-Mix.
Histochemical analysis
Skeletal muscle and heart were fixed for 12 to 24 h in formalin,
embedded in paraffin and sectioned. To determine muscle
morphology, sections were stained with hematoxylin/eosin.
Glycogen content was analyzed by Periodic Acid Schiff (PAS)
staining. Heart fibrosis was determined by Masson trichrome
staining. For histochemical analysis of succinate dehydrogenase
(SDH) and NADH-tetrazolium reductase (NADH-TR) activities,
gastrocnemius muscle was dissected and frozen in isopentane
supercooled with liquid nitrogen. Frozen sections were analyzed as
previously indicated [51,52].
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For immunohistochemical detection of VEGF and collagen IV
proteins, paraffin sections were incubated overnight at 4uC with
rabbit anti-mouse VEGF antibody (Santa Cruz) diluted at 1:50
and with rabbit anti-mouse collagen IV antibody (Chemicon Inc.)
diluted at 1:100. For immunohistochemical detection of PECAM-
1, cryosections were incubated overnight at 4uC with rat anti-
mouse PECAM-1 antibody (Pharmingen BDbiosciences) diluted at
1:100. Afterwards, samples were incubated with the biotinylated
secondary antibodies (dilution 1:200): Rabbit against rat IgG
(Vector laboratories) or goat against rabbit IgG (Vector labora-
tories). The localization of VEGF was determined using
streptavidin conjugate Alexa fluor 488 (Molecular Probes),
collagen IV using streptavidin conjugate Alexa fluor 568
(Molecular Probes) and PECAM-1 by ABC peroxidase mouse
IgG staining kit (Pierce Biotechnology).
Transmission electron microscopic analysis
Skeletal and cardiac muscle samples were obtained and fixed in
2.5% glutaraldehyde and 2% paraformaldehyde for 2 h at 4uC.
After washing in cold cacodylate buffer, the specimens were
postfixed in 1% osmium tetroxide, stained in aqueous uranyl
acetate, and then dehydrated through a graded ethanol series and
embedded in epoxy resin. Ultrathin sections (600–800 A ˚) from the
resin blocks were stained using lead citrate and examined in a
transmission electron microscopy (Hitachi H-7000).
Statistical analysis
All values were expressed as mean6SEM. Two-tailed P values
were calculated by unpaired Student’s t test. Differences were
considered statistically significant at P values less than 0.05.
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